» Articles » PMID: 23592885

RNAi Therapeutics and Applications of MicroRNAs in Cancer Treatment

Overview
Specialty Oncology
Date 2013 Apr 18
PMID 23592885
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

RNA interference-based therapies are proving to be powerful tools for combating various diseases, including cancer. Scientists are researching the development of safe and efficient systems for the delivery of small RNA molecules, which are extremely fragile in serum, to target organs and cells in the human body. A dozen pre-clinical and clinical trials have been under way over the past few years involving biodegradable nanoparticles, lipids, chemical modification and conjugation. On the other hand, microRNAs, which control the balance of cellular biological processes, have been studied as attractive therapeutic targets in cancer treatment. In this review, we provide an overview of RNA interference-based therapeutics in clinical trials and discuss the latest technology for the systemic delivery of nucleic acid drugs. Furthermore, we focus on dysregulated microRNAs in human cancer, which have progressed in pre-clinical trials as therapeutic targets, and describe a wide range of strategies to control the expression levels of endogenous microRNAs. Further development of RNA interference technologies and progression of clinical trials will contribute to the achievement of practical applications of nucleic acid drugs.

Citing Articles

The two sides of chromosomal instability: drivers and brakes in cancer.

Hosea R, Hillary S, Naqvi S, Wu S, Kasim V Signal Transduct Target Ther. 2024; 9(1):75.

PMID: 38553459 PMC: 10980778. DOI: 10.1038/s41392-024-01767-7.


The strict regulation of HIF-1α by non-coding RNAs: new insight towards proliferation, metastasis, and therapeutic resistance strategies.

Jawad S, Altalbawy F, Hussein R, Fadhil A, Abed Jawad M, Zabibah R Cancer Metastasis Rev. 2023; 43(1):5-27.

PMID: 37552389 DOI: 10.1007/s10555-023-10129-8.


Advances in Chitosan-based Drug Delivery Systems in Melanoma: A Narrative Review.

Dana P, Hallajzadeh J, Asemi Z, Mansournia M, Yousefi B Curr Med Chem. 2023; 31(23):3488-3501.

PMID: 37202890 DOI: 10.2174/0929867330666230518143654.


A Systematic Review of Clinical Validated and Potential miRNA Markers Related to the Efficacy of Fluoropyrimidine Drugs.

Sun X, Chen J, Chen X, Gao Q, Chen W, Zou X Dis Markers. 2022; 2022:1360954.

PMID: 36051356 PMC: 9427288. DOI: 10.1155/2022/1360954.


MicroRNA as a Potential Therapeutic Molecule in Cancer.

Szczepanek J, Skorupa M, Tretyn A Cells. 2022; 11(6).

PMID: 35326459 PMC: 8947269. DOI: 10.3390/cells11061008.